Disease · HP_0100543
Comparisons in its trials65
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 65
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Dexmedetomidine vs Propofol: Death at 90 Days | 81 of 214 | 82 of 208 | 422 | NCT01739933 | Trial comparisons |
| Dexmedetomidine vs Propofol: deaths from any cause | 89 of 214 | 86 of 208 | 422 | NCT01739933 | Trial comparisons |
| Dexmedetomidine vs Propofol: serious adverse events | 0 of 214 | 0 of 208 | 422 | NCT01739933 | Trial comparisons |
| Donepezil vs Placebo: deaths from any cause | 0 of 140 | 0 of 136 | 276 | NCT02822573 | Trial comparisons |
| Donepezil vs Placebo: serious adverse events | 12 of 140 | 8 of 136 | 276 | NCT02822573 | Trial comparisons |
| Insulin (Humulin® R U-100) vs Placebo: deaths from any cause | 1 of 121 | 0 of 119 | 240 | NCT01767909 | Trial comparisons |
| Insulin (Humulin® R U-100) vs Placebo: serious adverse events | 18 of 121 | 10 of 119 | 240 | NCT01767909 | Trial comparisons |
| Peptide T vs Placebo: serious adverse events | 8 of 106 | 3 of 109 | 215 | NCT00000392 | Trial comparisons |
| Candesartan vs Lisinopril: deaths from any cause | 0 of 87 | 0 of 89 | 176 | NCT01984164 | Trial comparisons |
| Candesartan vs Lisinopril: serious adverse events | 0 of 87 | 0 of 89 | 176 | NCT01984164 | Trial comparisons |
| CX516 vs Placebo: deaths from any cause | 0 of 84 | 0 of 91 | 175 | NCT00040443 | Trial comparisons |
| CX516 vs Placebo: serious adverse events | 3 of 84 | 1 of 91 | 175 | NCT00040443 | Trial comparisons |
| Valacyclovir vs Placebo: deaths from any cause | 0 of 84 | 0 of 86 | 170 | NCT02008773 | Trial comparisons |
| Valacyclovir vs Placebo: serious adverse events | 3 of 84 | 4 of 86 | 170 | NCT02008773 | Trial comparisons |
| Lovastatin vs Placebo: deaths from any cause | 0 of 74 | 0 of 70 | 144 | NCT00853580 | Trial comparisons |
| Lovastatin vs Placebo: serious adverse events | 6 of 74 | 1 of 70 | 144 | NCT00853580 | Trial comparisons |
| Minocycline vs Matching Placebo: serious adverse events | 7 of 52 | 3 of 55 | 107 | NCT00361257 | Trial comparisons |
| MK0249 vs Placebo: serious adverse events | 0 of 52 | 0 of 51 | 103 | NCT00506077 | Trial comparisons |
| Curcumin vs Placebo: deaths from any cause | 1 of 45 | 0 of 43 | 88 | NCT03223883 | Trial comparisons |
| Curcumin vs Placebo: serious adverse events | 0 of 45 | 0 of 43 | 88 | NCT03223883 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/HP_0100543/comparisons